olanzapine + ziprasidone

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Depression

Conditions

Depression, Schizophrenia, Schizoaffective Disorder

Trial Timeline

Sep 1, 2001 โ†’ Mar 1, 2003

About olanzapine + ziprasidone

olanzapine + ziprasidone is a approved stage product being developed by Eli Lilly for Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00034801. Target conditions include Depression, Schizophrenia, Schizoaffective Disorder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00034801ApprovedCompleted

Competing Products

20 competing products in Depression

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
QuetiapineAstellas PharmaPre-clinical
23
duloxetine + escitalopram + placeboEli LillyPhase 3
77
duloxetineEli LillyApproved
85
Duloxetine HydrochlorideEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
DuloxetineEli LillyApproved
85
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)Eli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
duloxetine + fluoxetine + citalopram + paroxetine + sertralineEli LillyApproved
85
Olanzapine + PlaceboEli LillyPhase 3
77
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
77
duloxetine + duloxetineEli LillyPre-clinical
23
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
85
Drug treatment with CymbaltaEli LillyApproved
85
DuloxetineEli LillyApproved
85
DuloxetineEli LillyApproved
85